Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease
Joseph W. Golden, Curtis R. Cline, Xiankun Zeng, et al.
JCI Insight (2020) Vol. 5, Iss. 19
Open Access | Times Cited: 217

Showing 1-25 of 217 citing articles:

The cGAS–STING pathway drives type I IFN immunopathology in COVID-19
Jérémy Di Domizio, Muhammet F. Gülen, Fanny Saidoune, et al.
Nature (2022) Vol. 603, Iss. 7899, pp. 145-151
Open Access | Times Cited: 404
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Naveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2316-2331.e15
Open Access | Times Cited: 382
Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
Fatai S. Oladunni, Jun‐Gyu Park, Paula A. Pino, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 368
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Emma S. Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Cell (2021) Vol. 184, Iss. 7, pp. 1804-1820.e16
Open Access | Times Cited: 349
K18-hACE2 mice develop respiratory disease resembling severe COVID-19
Claude Kwe Yinda, Julia R. Port, Trenton Bushmaker, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 1, pp. e1009195-e1009195
Open Access | Times Cited: 292
Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice
Pratima Kumari, Hussin A. Rothan, Janhavi P. Natekar, et al.
Viruses (2021) Vol. 13, Iss. 1, pp. 132-132
Open Access | Times Cited: 255
SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration
Ling Zhang, Li Zhou, Linlin Bao, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 245
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
Irfan Ullah, Jérémie Prévost, Mark S. Ladinsky, et al.
Immunity (2021) Vol. 54, Iss. 9, pp. 2143-2158.e15
Open Access | Times Cited: 193
Animal and translational models of SARS-CoV-2 infection and COVID-19
Matt D. Johansen, Aaron T. Irving, Xavier Montagutelli, et al.
Mucosal Immunology (2020) Vol. 13, Iss. 6, pp. 877-891
Open Access | Times Cited: 176
Defining the risk of SARS-CoV-2 variants on immune protection
Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, et al.
Nature (2022) Vol. 605, Iss. 7911, pp. 640-652
Open Access | Times Cited: 152
Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia
Lucie Bernard, Mericien Venzon, Jon Klein, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 128
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
Kun Li, David K. Meyerholz, Jennifer A. Bartlett, et al.
mBio (2021) Vol. 12, Iss. 4
Open Access | Times Cited: 125
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Ahmed O. Hassan, Swathi Shrihari, Matthew J. Gorman, et al.
Cell Reports (2021) Vol. 36, Iss. 4, pp. 109452-109452
Open Access | Times Cited: 119
The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models
Rafał Butowt, Nicolas Meunier, Bertrand Bryche, et al.
Acta Neuropathologica (2021) Vol. 141, Iss. 6, pp. 809-822
Open Access | Times Cited: 117
Neurological complications and infection mechanism of SARS-CoV-2
Dandan Wan, Tingfu Du, Weiqi Hong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 111
Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression
Mariano Carossino, Devin Kenney, Aoife K. O’Connell, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 535-535
Open Access | Times Cited: 69
Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants
Mengfei Chen, Andrew Pekosz, Jason Villano, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 8
Open Access | Times Cited: 17
The Potential Intermediate Hosts for SARS-CoV-2
Jie Zhao, Wei Cui, Baoping Tian
Frontiers in Microbiology (2020) Vol. 11
Open Access | Times Cited: 133
Endothelial cell infection and dysfunction, immune activation in severe COVID-19
Zhongnan Qin, Fengming Liu, Robert V. Blair, et al.
Theranostics (2021) Vol. 11, Iss. 16, pp. 8076-8091
Open Access | Times Cited: 98
In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin
Sakshi Piplani, Puneet Kumar Singh, David A. Winkler, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 97
A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
Laura A. VanBlargan, Lucas J. Adams, Zhuoming Liu, et al.
Immunity (2021) Vol. 54, Iss. 10, pp. 2399-2416.e6
Open Access | Times Cited: 94
Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
David A. Meekins, Natasha N. Gaudreault, Jüergen A. Richt
Viruses (2021) Vol. 13, Iss. 10, pp. 1993-1993
Open Access | Times Cited: 93
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody
Conrad En Zuo Chan, Shirley G. K. Seah, De Hoe Chye, et al.
PLoS ONE (2021) Vol. 16, Iss. 6, pp. e0253487-e0253487
Open Access | Times Cited: 92
Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model
Santosh Dhakal, Camilo A. Ruiz-Bedoya, Ruifeng Zhou, et al.
mBio (2021) Vol. 12, Iss. 4
Open Access | Times Cited: 90
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
Elaine C. Chen, Pavlo Gilchuk, Seth J. Zost, et al.
Cell Reports (2021) Vol. 36, Iss. 8, pp. 109604-109604
Open Access | Times Cited: 89
Page 1 - Next Page

Scroll to top